Mani Foroohar analyst LEERINK

Currently out of the existing stock ratings of Mani Foroohar, 118 are a BUY (53.64%), 87 are a HOLD (39.55%), 15 are a SELL (6.82%).

Mani Foroohar

Work Performance Price Targets & Ratings Chart

Analyst Mani Foroohar, currently employed at LEERINK, carries an average stock price target met ratio of 49.83% that have a potential upside of 42.9% achieved within 196 days.

Mani Foroohar’s has documented 401 price targets and ratings displayed on 25 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BBIO, BridgeBio Pharma at 17-Oct-2024.

Wall Street Analyst Mani Foroohar

Analyst best performing recommendations are on FDMT (4D MOLECULAR THERAPEUTICS ).
The best stock recommendation documented was for FDMT (4D MOLECULAR THERAPEUTICS ) at 11/14/2022. The price target of $15 was fulfilled within 1 day with a profit of $1.51 (11.19%) receiving and performance score of 111.93.

Average potential price target upside

ADVM Adverum Biotechnologies ALNY Alnylam Pharmaceuticals ARWR Arrowhead Pharmaceuticals BBIO BridgeBio Pharma BLUE Bluebird bio CRBU Caribou Biosciences DBTX Decibel Therapeutics DRNA Dicerna Pharmaceuticals IONS Ionis Pharmaceuticals MRNA Moderna NTLA Intellia Therapeutics RCKT Rocket Pharmaceuticals RGNX Regenxbio RXRX Recursion Pharmaceuticals WVE Wave Life Sciences Ltd SRPT Sarepta Therapeutics ABEO Abeona Therapeutics ALVR Allovir  FDMT 4D Molecular Therapeutics  MIRM Mirum Pharmaceuticals AMYT Amryt Pharma Holdings Ltd GRPH Graphite Bio TALS Talaris Therapeutics EDIT Editas Medicine BEAM Beam Therapeutics 

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$12

$4.59 (61.94%)

$30

2 months 26 days ago
(13-Aug-2024)

1/5 (20%)

$5.24 (77.51%)

35

Buy

$30

$22.59 (304.86%)

$30

2 months 26 days ago
(13-Aug-2024)

0/3 (0%)

$23.24 (343.79%)

Buy

$40

$32.59 (439.81%)

$4

3 months 21 days ago
(18-Jul-2024)

1/4 (25%)

$30.52 (321.94%)

543

Buy

$22

$14.59 (196.90%)

$40

6 months 10 days ago
(29-Apr-2024)

2/5 (40%)

$12.47 (130.85%)

52

Buy

$6

$4.05 (207.69%)

$4

1 years 2 months 3 days ago
(05-Sep-2023)

4/7 (57.14%)

$4.22 (237.08%)

196

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Mani Foroohar is most bullish on?

Potential upside of $106.71 has been obtained for SRPT (SAREPTA THERAPEUTICS)

Which stock is Mani Foroohar is most reserved on?

Potential downside of $1.6 has been obtained for RXRX (RECURSION PHARMACEUTICALS)

What Year was the first public recommendation made by Mani Foroohar?

On 2018

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?